Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
B1SX34 | B3 | BRL | Delayed | |
BSX | NYSE | USD | Real-time | |
BSX | BIVA | MXN | Delayed | |
1BSX | Milan | EUR | Real-time | |
BSXU | TradeGate | EUR | Delayed | |
BSXU | Vienna | EUR | Real-time |
Boston Scientific Corporation reported earnings results for the third quarter and nine months ended September 30, 2024. For the third quarter, the company reported sales was USD 4,209 million compared to USD 3,527 million a year ago. Net income was USD 468 million compared to USD 504 million a year ago. Basic earnings per share from continuing operations was USD 0.32 compared to USD 0.34 a year ago. Diluted earnings per share from continuing operations was USD 0.32 compared to USD 0.34 a year ago. For the nine months, sales was USD 12,186 million compared to USD 10,515 million a year ago. Net income was USD 1,280 million compared to USD 1,088 million a year ago. Basic earnings per share from continuing operations was USD 0.88 compared to USD 0.74 a year ago. Diluted earnings per share from continuing operations was USD 0.87 compared to USD 0.73 a year ago.
Period Ending: | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
---|---|---|---|---|
Total Revenue | 4209 | 4120 | 3856 | 3725 |
Gross Profit | 2892 | 2841 | 2637 | 2567 |
Operating Income | 718 | 799 | 693 | 617 |
Net Income | 468 | 324 | 494 | 504 |
Period Ending: | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
---|---|---|---|---|
Total Assets | 38078 | 37108 | 36669 | 35136 |
Total Liabilities | 17122 | 16499 | 16501 | 15606 |
Total Equity | 20956 | 20609 | 20168 | 19530 |
Period Ending: | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 1002 | 813 | 164 | 957 |
Cash From Investing Activities | -1427 | -271 | -285 | -1053 |
Cash From Financing Activities | 7 | 24 | 1569 | 15 |
Net Change in Cash | -412 | 565 | 1441 | -77 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review